LBPMedicine(SH:688393) Mei Ri Jing Ji Xin Wen·2026-01-30 08:09Group 1 - The company Anbiping expects a net loss attributable to shareholders of the parent company for 2025, ranging from -52 million to -42 million yuan, representing a year-on-year decline of 344.23% to 297.26% [1] - The primary reason for the performance change is the impact of the main business, with a significant decrease in operating income and net profit due to the implementation of national centralized procurement policies [1] - The company's HPV product line experienced a notable price drop, leading to a revenue decrease of approximately 46.5 million yuan and a corresponding decline in gross profit margin [1] Group 2 - The company is actively optimizing its business structure by focusing on expanding its main business revenue and reducing the scale of agency product business [1] - To enhance market penetration, the company is adjusting its channel strategy to increase the proportion of distribution channels, which may temporarily affect overall gross profit but improves customer coverage efficiency [1] - The company is strengthening its product research and innovation efforts, particularly in the fields of digital pathology and tumor companion diagnostics, which has led to an increase in operating costs but lays a solid foundation for sustainable future development [1]